Identification and use of agents that modulate oncogenic...

Details Identification and use of agents that modulate oncogenic... Identification and use of agents that modulate oncogenic...

2007-10-01

2011-10-04

Goddard, Laura B (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S008000

Reexamination Certificate

active

08029980

ABSTRACT:
Embodiments of the invention provides, among other things, methods for identifying agents that inhibit oncogenic transcription factors, induce apoptosis, inhibit the growth of transformed cells and cancer cells, and potentiate the effects of other agents that induce apoptosis and that inhibit the growth of transformed cells and cancer cells. Embodiments of the invention further provide compositions useful for the same comprising an agent the inhibits one or more oncogenic transcription factors and an agent that induces apoptosis, particular compositions wherein the apoptotic effect of the combination is greater than either agent by itself. Embodiments of the invention further provide for the use of such agents and compositions to treat cancer. In illustrative embodiments the agents that inhibit transcription factor activity are thiazole antibiotics, such as Siomycin and thiostrepton, and the apoptosis inducing agent is a member of the TNF ligand superfamily, such as TNF-alpha. In illustrative embodiments the cancers are those in which both the FoxM1 and the NF-kB oncogenic pathways are activated.

REFERENCES:
patent: 4064013 (1977-12-01), Meyers et al.
patent: 5723313 (1998-03-01), Sherr et al.
patent: 6172194 (2001-01-01), Sherr et al.
patent: 6376175 (2002-04-01), Foulkes et al.
patent: 6407062 (2002-06-01), Sherr et al.
patent: 7635673 (2009-12-01), Costa et al.
patent: 2002/0155988 (2002-10-01), O'Hare et al.
patent: 2002/0156023 (2002-10-01), Walling et al.
patent: 2002/0193325 (2002-12-01), Depinho
patent: 2005/0032692 (2005-02-01), Costa et al.
patent: 2006/0014688 (2006-01-01), Costa et al.
patent: 2009/0075376 (2009-03-01), Cossta et al.
patent: WO0160374 (2001-08-01), None
patent: WO0226236 (2002-04-01), None
patent: WO02083140 (2002-10-01), None
patent: WO02092013 (2002-11-01), None
patent: WO2004018676 (2004-03-01), None
patent: WO2004019761 (2004-03-01), None
patent: WO2004100977 (2004-11-01), None
patent: WO2005054870 (2005-06-01), None
patent: WO2006/009575 (2006-01-01), None
patent: WO2007109609 (2007-09-01), None
patent: WO2008095112 (2008-08-01), None
Bowie (Science, 1990, 257:1306-1310).
By Burgess et al ( J of Cell Bio. 111:2129-2138, 1990).
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).
Harris et al. J. of The Am Society of Nephrology 6:1125-33, 1995.
Ahn et al. Nature Genetics 3(4):283-91, 1993.
Cawthon et al. Genomics 9(3):446-60, 1991).
Laoukili et al., “FoxM1 is Required for Execution of the Mitotic Programme and Chromosome Stability”, Nature Cell Biology, vol. 7, No. 2, Feb. 2005, pp. 126-136; pp. 1-4.
Wang et al., “Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin Ligase”, Molecular and Cellular Biology, Dec. 2005, vol. 25, No. 24, pp. 10875-10894.
Robert H. Costa, “FoxM1 Dances With Mitosis”, Nature Cell Biology, vol. 7, No. 2, Feb. 2005, pp. 108-110.
Ye et al., “Hepatocyte Nuclear Factor 3/Fork Head Homolog 121 is Expressed in Proliferating Epithelial and Mesenchymal Cells of Embryonic and Adult Tissues”, Molecular and Cellular Biology, vol. 17, No. 3, Mar. 1997, pp. 1626-1641.
Ye et al., “Premature Expression of the Winged Helix Transcription Factor HFH-11B in Regenerating Mouse Liver Accelarates Hepatocyte Entry into S Phase”, Molecular and Cellular Biology, Vo. 19, No. 12, Dec. 1999, pp. 8570-8580.
Korver et al., “The Winged-helix Transcription Factor Trident is Expressed in Cycling Cells”, Nucleic Acids Research, 1997, vol. 25, No. 9, pp. 1715-1719.
Yao et al., “Molecular Analysis of a Novel Winged Helix Protein, WIN”, The Journal of Biological Chemistry, vol. 272, No. 32, Issue of Aug. 8, 1997, pp. 19827-19836.
Wonsey et al., “Loss of the Forkhead Transcription Factor FoxM1 Causes Centrosome Amplification and mitotic Catastrophe”, Cancer Research 2005; 65: (12) Jun. 15, 2005, pp. 5181-5189.
Teh et al., “FoxM1 is a Downstream Target of Gli1 in Basal Cell Carcinomas”, Cancer Research 62, Aug. 15, 2002, pp. 4773-4780.
Okabe et al., “Genome-wide Analysis of Gene Expression in Human Hepatocellular Carcinomas Using cDNA Microarray: Identification of Genes Involved in viral Carcinogenesis and Tumor Progression”, Cancer Research 61, Mar. 1, 2001, pp. 2129-2137.
Lee et al., “Classification and Prediction of Survival in Hepatocellular Carcinoma by Gene Expression Profiling”, Hepatology, Vo. 40, No. 3, Sep. 2004, pp. 667-676.
Obama et al., “Genome-Wide Analysis of Gene Expression in Human Intrahepatic Cholangiocarcinoma”, Hepatology, vol. 41, No. 6, Jun. 2005, pp. 1339-1348.
Kim et al., “The Forkhead Box ml Transcription Factor Stimulates the Proliferation of Tumor Cells during Development of Lung Cancer”, Cancer Research, 66: (4), Feb. 15, 2006, pp. 2153-2161.
van den Boom et al., “Characterization of Gene Expression Profiles Associated with Glioma Progression Using Oligonucleotide-Based Microarray Analysis and Real-Time Reverse Transcription-Polymerase Chain Reaction”, American Journal of Pathology, vol. 163, No. 3, Sep. 2003, pp. 1033-1043.
Kalin et al., “Increased Levels of the FoxM1 Transcription Factor Accelerate Development and Progression of Prostate Carcinomas in both TRAMP and LADY Transgenic Mice”. Cancer Research, Feb. 1, 2006; 66(3): pp. 1712-1720.
Pilarsky et al., “Identification and Validation of Commonly Overexpressed Genes in Solid Tumors by Comparison of Microarray Data”. Neoplasia, vol. 6, No. 6, Nov./Dec. 2004, pp. 744-750.
Kalinichenko et al., “Foxm1b Transcription Factor is Essential for Development of Hepatocellular Carcinomas and is Negatively Regulated by the p19 ARF Tumor Suppressor”. Genes & Development, 2004, 18: pp. 830-850.
Radhakrishnan et al., “Constitutive Expression of E2F-1 Leads to P21-Dependent Cell Cycle Arrest in S Phase of the Cell Cycle”, Oncogene, 2004, 23, pp. 4173-4176.
Radhakrishnan et al., “The PPAR-Y Agonist Pioglitazone Post-Transcriptionally Induces p21 in PC3 Prostate Cancer but not in Other Cells Lines”, Cell Cycle, vol. 4, Issue 4, 2005, pp. 582-584.
Radhakrishnan et al., “Multiple Alternate p21 Transcripts are Regulated by p53 in Human Cells”. Oncogene (2006) 25, pp. 1812-1815.
Cozen et al., “Induction of Cell Cycle Progression and Acceleration of Apoptosis are two Separable Functions of c-Myc: Transrepression Correlates with Acceleration of Apoptosis”. Molecular and Cellular Biology, vol. 20, No. 16, Aug. 2000, pp. 6008-6018.
Major et al., “Forkhead Box M1B Transcription Activity Requires Binding of Cdk-Cyclin Complexes for Phosphorylation-Dependent Recruitment of p300/CBP Coactivators”. Molecular and Cellular Biology, vol. 24, No. 7, Apr. 2004, pp. 2649-2661.
Lentzen et al. “Structural Basis for Contrasting Activities of Ribosome Binding Thiazole Antibiotics”. Chemistry & Biology, vol. 10, Aug. 2003, pp. 769-778.
Radhakrishnan et al., “A Novel Transcriptional Inhibitor Induces Apoptosis in Tumor Cells and Exhibits Antiangiogenic Activity”. Cancer Research, vol. 66, No. 6, Mar. 15, 2006, pp. 3264-3270.
Weinstein, “Addiction to Oncogenes—the Achilles Heal of Cancer”. Science, vol. 297, Jul. 5, 2002, pp. 63-64.
Hagg et al. “A Novel High-through-Put Assay for Screening of Pro-Apoptotic Drugs”. Investigational New Drugs, vol. 20, 2002, pp. 253-259.
Erdal et al., “Induction of Lysosomal Membrane Permeabilization by Compounds That Activate p53 Independent Apoptosis”. PNAS, Jan. 4, 2005, vol. 102, No. 1, pp. 192-197.
Monga et al., “Developmental Therapeutics Program at the NCI: Molecular Target and Drug Discovery Process”. Leukemia (2002) 16, pp. 520-526.
Nicolaou et al., “Discovery of a Biologically Active Thiostrepton Fragment”. J. Am. Chem. Soc., 2005, 127 (43), pp. 15042-15044.

Affiliated with

Also associated with

Rating

Identification and use of agents that modulate oncogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Identification and use of agents that modulate oncogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification and use of agents that modulate oncogenic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4285295